Abstract:Background: Lactate, previously considered a metabolic byproduct, is pivotal in cancer progression and maintaining the immunosuppressive tumor microenvironment. Further investigations confirmed that lactate is a primary regulator, introducing recently described post-translational modifications of histone and non-histone proteins, termed lysine lactylation. Pancreatic adenocarcinomas are characterized by increased glycolysis and lactate accumulation. However, our understanding of lactylation-related genes in pancreatic adenocarcinomas remains limited. Aim: To construct a novel lactylation-related gene signature to predict the survival of patients with pancreatic cancer. Methods: RNA-seq and clinical data of pancreatic adenocarcinoma (PDAC) were obtained from the GTEx (Genotype-Tissue Expression) and TCGA (The Cancer Genome Atlas) databases via Xena Explorer, and GSE62452 datasets from GEO. Data on lactylation-related genes were obtained from publicly available sources. Differential expressed genes (DEGs) were acquired by using R package "DESeq2" in R. Univariate COX regression analysis, LASSO Cox and multivariate Cox regressions were produced to construct the lactylation-related prognostic model. Further analyses, including functional enrichment, ESTIMATE, and CIBERSORT, were performed to analyze immune status and treatment responses in patients with pancreatic cancer. PDAC and normal human cell lines were subjected to western blot analysis under lactic acid intervention; two PDAC cell lines with the most pronounced lactylation were selected. Subsequently, RT-PCR was employed to assess the expression of LRGs genes; SLC16A1, which showed the highest expression, was selected for further investigation. SLC16A1-mediated lactylation was analyzed by immunofluorescence, lactate production analysis, colony formation, transwell, and wound healing assays to investigate its role in promoting the proliferation and migration of PDAC cells. In vivo validation was performed using an established tumor model. Results: In this study, we successfully identified 10 differentially expressed lactylation-related genes (LRGs) with prognostic value. Subsequently, a lactylation-related signature was developed based on five OS-related lactylation-related genes (SLC16A1, HLA-DRB1, KCNN4, KIF23, and HPDL) using Lasso Cox hazard regression analysis. Subsequently, we evaluated the clinical significance of the lactylation-related genes in pancreatic adenocarcinoma. A comprehensive examination of infiltrating immune cells and tumor mutation burden was conducted across different subgroups. Furthermore, we demonstrated that SLC16A1 modulates lactylation in pancreatic cancer cells through lactate transport. Both in vivo and in vitro experiments showed that decreasing SLC16A1 Level and its lactylation significantly inhibited tumor progression, indicating the potential of targeting the SLC16A1/Lactylation-associated signaling pathway as a therapeutic strategy against pancreatic adenocarcinoma. Conclusion: We constructed a novel lactylation-related prognostic signature to predict OS, immune status, and treatment response of patients with pancreatic adenocarcinoma, providing new strategic directions and antitumor immunotherapies.

Identification of a novel lactylation-related gene signature predicts the prognosis of multiple myeloma and experiment verification

Identification of Lactylation Gene CALML5 and Its Correlated Lncrnas in Cutaneous Melanoma by Machine Learning.

A novel ferroptosis-related gene signature for predicting prognosis in multiple myeloma

Identification and Evaluation of a Six-Lncrna Prognostic Signature for Multiple Myeloma

Identification of lipid metabolism-related gene signature in the bone marrow microenvironment of multiple myelomas through deep analysis of transcriptomic data

A novel glycolysis-related gene signature for predicting the prognosis of multiple myeloma

Identification and Validation of a Novel RNA-Binding Protein-Related Gene-Based Prognostic Model for Multiple Myeloma

Upregulation of Lncrna NR_046683 Serves As a Prognostic Biomarker and Potential Drug Target for Multiple Myeloma

Identification and validation of a platelet-related signature for predicting survival and drug sensitivity in multiple myeloma

Novel lactylation-related signature to predict prognosis for pancreatic adenocarcinoma

One-lincRNA and Five-Mrna Based Signature for Prognosis of Multiple Myeloma Patients Undergoing Proteasome Inhibitors Therapy

Identification of a novel cuproptosis-related gene signature for multiple myeloma diagnosis

Developing mRNA signatures as a novel prognostic biomarker predicting high risk multiple myeloma

Predicting lymphoma prognosis using machine learning-based genes associated with lactylation

Characterization of a Lactate Metabolism-Related Signature for Evaluation of Immune Features and Prediction Prognosis in Glioma.

Identification of a Mitochondria-Related Gene Signature to Predict the Prognosis in AML

Identification of microtubule-associated biomarkers in diffuse large B-cell lymphoma and prognosis prediction

Identification of Immune-Related Genes for Risk Stratification in Multiple Myeloma Based on Whole Bone Marrow Gene Expression Profiling

Identification and validation of a cellular senescence-related lncRNA signature for prognostic prediction in patients with multiple myeloma

A Novel Model of Tumor-Infiltrating B Lymphocyte Specific RNA-Binding Protein-Related Genes With Potential Prognostic Value and Therapeutic Targets in Multiple Myeloma

Identification Of Potential Prognostic Biomarker For Predicting Survival In Multiple Myeloma Using Bioinformatics Analysis And Experiments